# Wu Capital

> Wu Capital is a VC fund in Beijing backing Health Care and Biotechnology. See 44 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 44
- Last investment: Dec 2024
- Lead investor: 36%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/wu-capital
- Website: http://www.wu-capital.com

Wu Capital is a VC fund in Beijing focused on Health Care and Biotechnology. Wu Capital operates as an investment company. It invests in technology, media, telecom (TMT), healthcare, fintech, high-tech, offline experience consumptions, virtual experience consumptions, culture and Sports, and other related fields. Wu Capital operates business worldwide. It has its headquarters in Beijing in China.

## Contacts

5 contacts available for Wu Capital. Shizune tracks 5 team members at Wu Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wu-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.9M–$100M |
| Series B | $3M–$116M |
| Series C | $8.9M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 23% |
| Biotechnology | 8 | 18% |
| Education | 6 | 14% |
| Pharmaceutical | 6 | 14% |
| Artificial Intelligence | 5 | 11% |

56 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 18 | 41% |
| Series B | 12 | 27% |
| Series C | 6 | 14% |
| Angel | 1 | 2% |
| Series D | 1 | 2% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 25 | 57% |
| United States | 10 | 23% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexa Zhang | Managing Director / Global Head of Fund Investing | 0 | https://shizune.co/investors/profile/alexa-zhang |
| Martin Tian | Director of human resources | 0 | https://shizune.co/investors/profile/martin-tian |
| Mingming Li | Chief Technology Officer | 0 | https://shizune.co/investors/profile/mingming-li-c61f |
| Rita Zhang | CEO | 1 | https://shizune.co/investors/profile/yan-zhang-5171 |
| Yunpeng Xia | Chief operating officer | 0 | https://shizune.co/investors/profile/yunpeng-xia |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nuvig Therapeutics | Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases. | $161M | Series B | Dec 05, 2024 |  |
| Ray Therapeutics | Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $100M | Series A | May 16, 2023 |  |
| Nuvig Therapeutics | Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases. | $47M | Series A | May 11, 2022 |  |
| Rona Therapeutics | Rona Therapeutics is a RNA therapeutics platform enabling discovery and development of modular and programmable RNA medicines. | $33M | Series A | Apr 07, 2022 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $116M | Series B | Jan 05, 2022 |  |
| RiVAI | RiVAI is an AI chip R&D company that develops processors and AI chip products. |  | Series A | Sep 23, 2021 |  |
| Ranok Therapeutics | Ranok is a privately held, pre clinical stage bio company that is pioneering an innovative targeted protein degradation technology. | $40M | Series B | Aug 19, 2021 |  |
| Feiliu | Feiliu is a provider of enterprise supply chain management and optimization technology based on artificial intelligence. The company is based in Shanghai, Shanghai, China. | $31.4M | Series A | May 31, 2021 |  |
| Laiye | Laiye is a digital workforce platform that empowers organizations by integrating AI Agents to boost employee productivity and creativity. The platform combines various intelligent automation capabilities, including RPA and IDP, to streamline operations and enhance business outcomes. | $50M | Series C | Apr 21, 2021 |  |
| Gemini Therapeutics | Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies,recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics. | $95M | Post-IPO Equity | Feb 08, 2021 |  |

10 of 44 investments shown.

## Co-investors
- [Luminous Ventures (former Lightspeed China Partners)](https://shizune.co/investors/profile/lightspeed-china-partners) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 3 deals together
- [Eight Roads Ventures](https://shizune.co/investors/profile/eight-roads-ventures) — VC Fund, 3 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Coinbase Ventures](https://shizune.co/investors/profile/coinbase-ventures) — VC Fund
- [Polychain](https://shizune.co/investors/profile/polychain-capital) — VC Fund
- [Digital Currency Group](https://shizune.co/investors/profile/digital-currency-group) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Cryptocurrency Investors in China](https://shizune.co/investors/cryptocurrency-investors-china)
- [Cryptocurrency VC Funds in China](https://shizune.co/investors/cryptocurrency-vc-funds-china)

## FAQ

### What does Wu Capital invest in?

Wu Capital invests primarily in Health Care, Biotechnology and Education startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Wu Capital's check size?

Wu Capital typically joins rounds of $5.9M–$100M at Series A, $3M–$116M at Series B and $8.9M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wu Capital participates in.

### How do I contact Wu Capital?

Public channels for Wu Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Wu Capital?

The team at Wu Capital includes Alexa Zhang (Managing Director / Global Head of Fund Investing), Martin Tian (Director of human resources) and Mingming Li (Chief Technology Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co